Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-04-11

Clinical Trial Update: Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 augmentation trial of levetiracetam for obsessive-compulsive disorder was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVETIRACETAM (levetiracetam)

Snippet

Sponsor: Duke University | Conditions: Obsessive-Compulsive Disorder | Phase 2, Phase 3 | Status: TERMINATED